UCB — Board/Management Information 2022

Mar 25, 2022

Jean-Christophe TELLIER

Chief Executive Officer Chairman of the Executive Committee Member of the Board since 2014 Date of birth: 1959 Nationality: French Gender: Male End of term: 2022

Introduction & Professional experience

Jean-Christophe Tellier joined UCB in 2011. He became UCB's Chief Executive Officer on January 1, 2015 after having successfully led UCB's BioBrands and Solutions division as Executive Vice President.

He is a member of the Board of Directors of UCB, Chair of BCR (Biopharmaceutical CEOs Roundtable), President IFPMA (International Federation of Pharmaceutical Manufacturers & Associations), Member of the Board of the European Federation of Pharmaceutical Associations (EFPIA) and Vice-Chair of the Innovation Board Sponsored Committee (EFPIA). He is also a member of the Board of PhRMA (Pharmaceutical Research and Manufacturers of America).

Jean-Christophe Tellier is an experienced global leader. He was trained as a Medical Doctor and specialized in rheumatology. He has built a distinguished 30+ year career in the biopharmaceutical industry, taking on different global leadership responsibilities in different parts of the world.

His patient-centric approach, his passion for science, combined with his strategic and operational skills, have allowed him to significantly contribute to UCB's success. Jean-Christophe believes that the best way to have a positive impact on society and continue to thrive is to deliver on our commitments to patients and create impact for our employees, our shareholders, and our communities, all while respecting the planet. To this end he has led the integration of our sustainability approach into our

strategy to help UCB improve its societal impact while ensuring that we continue to perform well as a company.

He has also been instrumental in humanizing UCB's approach towards patients, developing the company's Patient Value Strategy. This strategy aims to act with focus and care to create value and make real improvements in the lives of the people UCB serves, ensuring we always see the person and not just the disease. For Jean-Christophe "engaging the patient in our vision is the best way for our company to be successful in the long term. Having a holistic view of a patient, of his/her life in his/her environment is essential to ensure effective treatment". Jean-Christophe also believes that "all healthcare players - physicians, payors, carers, industry and academia - should cooperate even more effectively and become stronger partners sharing a same goal: improving patient care".

As a leader, Jean-Christophe has always had a passion for developing people and fostering diversity and inclusion, which he sees as "a key force to drive company success". His ambition is to continue to further engage UCB teams behind the company's vision and fully leverage UCB's strong culture and talents.

Key positions

Prior to UCB, Jean-Christophe held the following positions:

2009	Ipsen: President and General Manager of Ipsen's North American operations
2008	Macrogenics: Maryland-based public biotechnology company – Executive Vice President and Chief Commercial Officer
1989 – 2008	Novartis: CEO of Novartis Pharma France
	CEO of Novartis Pharma Belgium – was President of the Board of the Belgian Pharma Trade association (pharma.be)
	Built his career in several local and global marketing and sales positions; was a.o. Head of Novartis' Global Business Franchise in Arthritis, Bone and Muscle Disease

Education

Doctor of Medicine (M.D.) – University of Reims Champagne-Ardenne, France Post-graduate: Rheumatologist – University of Paris V, France Executive business programs at Harvard and INSEAD

Main external appointments

Chair of BCR (Biopharmaceutical CEOs Roundtable) President of IFPMA (International Federation of Pharmaceutical Manufacturers & Associations) Member of the Board of the European Federation of Pharmaceutical Associations (EFPIA) Vice-Chair of the Innovation Board Sponsored Committee (EFPIA)

Member of the Board of PhRMA (Pharmaceutical Research and Manufacturers of America)